Smithfield Trust Co Has $50,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Smithfield Trust Co boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 55.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,739 shares of the company’s stock after buying an additional 980 shares during the quarter. Smithfield Trust Co’s holdings in Teva Pharmaceutical Industries were worth $50,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $28,000. EntryPoint Capital LLC bought a new position in Teva Pharmaceutical Industries during the first quarter worth $30,000. UMB Bank n.a. increased its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares during the last quarter. Claro Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at about $52,000. Finally, Beach Investment Counsel Inc. PA acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $48,000. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $17.12 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.35 and a fifty-two week high of $19.31. The stock has a fifty day moving average price of $17.70 and a 200-day moving average price of $17.30.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on TEVA shares. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group lifted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.